Nigel is a relative newcomer to academia. He established the Clostridia Research Group (CRG) in 2004, following 25 years of service in the applied environment of the Centre for Applied Microbiology and Research (CAMR), Porton Down. At CAMR he fulfilled a number of different roles, including Head of the Department of Molecular Microbiology as well as Scientific Leader for Molecular Microbiology for the establishment. To date he has filed 15 patents, secured £15.7M in funding since arriving at Nottingham, leads one of the six programmes that together comprise the BBSRC Sustainable Bioenergy Centre (BSBEC) and is the PI of a recently awarded BBSRC sLoLa in Synthetic Biology. He belongs to the TMO Renewables Ltd Centre of Excellence in Biorefining, is on the LanzaTech Scientific Advisory Board, has consulted for Pfizer, MERCK and Ipsen Pharmaceuticals and is the scientific lead on Clostridium difficile research within Nottingham's NIHR Biomedical Research Unit on Gastrointestinal disease.
Nigel (h-index 46) is a world expert in clostridial gene technologies and leads one of the largest research groups (ca. 60) at Nottingham, the CRG. Their remit is to:- (i) develop more effective countermeasures (diagnosis, prevention & treatment) against pathogens, specifically Clostridium difficile and Clostridium botulinum and (ii) to exploit the medical and industrial properties of beneficial strains, specifically in cancer therapy and in the production of chemical commodities from renewable resources. He has a proven track record of working with Industry, and the MTA portfolio dealing with the distribution of his patented tools is the largest within the University, with >250 MTAs drafted, and 24 licences and options granted. His group currently partner with a dozen or so companies, including TMO Renewables Ltd, Green Biologics Ltd, Weyland, LanzaTech, Unilever, Novartis, Metabolic Explorer and Phicotherapeutics. Moreover, he currently (2013) receives over £2.8M in direct industrial funding from Evonik, Lanxess, Invista, MERCK, Astellas, LanzaTech, Summit Plc, Bioseutica, Ipsen Pharmaceuticals Ltd and MucoVax. He is experienced in collaborative grants at all levels of scale, as both coordinator (5 past + 1 current EU grant) and vice-coordinator (2 X SysMO ERANETS), is a BSBEC Programme leader, holds BBSRC China & India partnership awards and a BBSRC ERANET-IBB grant and leads a BBSRC sLoLa, part funded by LanzaTech, focused on exploiting SynGas Fermentation though systems/ synthetic biology approaches.